Diabetes mellitus and co-morbid depression: Treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 261-266

  Abrahamian, Heidemarie ^a   Hofmann, Peter ^b   Prager, Rudolf ^a   Toplak, Hermann ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Depression; Diabetes; Metabolic control; Metformin; Milnacipran

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MILNACIPRAN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC REGULATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 69949126821     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s5421     Document Type: Article

References (34)

1. Katon WJ. The comorbidity of diabetes mellitus and depression. Am J Med. 2008;121(11 Suppl 2):S8-S15.
2. Ali S, Stone MA, Peters JL, et al. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165-1173. (Pubitemid 44600576)
3. Egede LE, Nietert PJ, Zheng D. Depression and All-Cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005;28:1339-1345. (Pubitemid 40756694)
4. Egede LE, Ellis C. The effects of depression on diabetes knowledge, diabetes self-management, and perceived control in indigent patients with type 2 diabetes. Diabetes Technol Ther. 2008;10:213-219. (Pubitemid 351677593)
5. Katon WJ, Russo JE, Von Korff M, et al. Long-term effects on medical costs of improving depression outcomes in patients with depression and diabetes. Diabetes Care. 2008;31:1155-1159.
6. DeGroot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: A meta-analysis. Psychosom Med. 2001;63:619-630. (Pubitemid 32695143)
7. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care. 2000;23:1556-1562. (Pubitemid 30746131)
8. Knol MJ, Twisk JW, Beekman AT, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49:837-845.
9. Dixon JB, Hayden MJ, Lambert GW, et al. Raised CRP levels in obese patients: symptoms of depression have an independent positive association. Obesity (Silver Spring). 2008;22 (Epub ahead of print).
10. Dong C, Sanchez LE, Price RA. Relationship of obesity to depression: a family-based study. Int J Obesity. 2004;28:790-795. (Pubitemid 38746225)
11. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799-812. (Pubitemid 47555203)
12. Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? Results from the third national health and nutrition examination survey. Am J Epidemiol. 2003;158:1139-1147. (Pubitemid 37548783)
13. Lustmann PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus. Arch Gen Psychiatry. 2006;63:521-529.
14. Gülseren L, Gülseren S, Hekimsoy Z, et al. Comparison of fluoxetine and paroxetine in type 2 diabetes mellitus patients. Arch Med Res. 2005;36:159-165. (Pubitemid 40545838)
15. Diagnosis and classification of diabetes mellitus, American Diabetes Association. Diabetes Care. 2006;29 Suppl 1:S43-S48.
16. Whooley MA, Avins AL, Miranda J, et al. Case-Finding Instrument for Depression. J Gen Intern Med. 1997;12:439-445.
17. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151-169.
18. Bech P, Rasmussen NA, Olsen LR, et al. The Sensivity and Specifity of the Major Depression Inventory, using the present State Examination as the index of diagnostic validity. J Affect Dis. 2001;88:159-164. (Pubitemid 32907521)
19. Austrian Diabetes Association. Therapeutic guidelines of the Austrian Diabetes Association http://www.oedg.org/pdf/Leitlinien-2007.pdf
20. Rush WA, Whitebird RR, Rush MR, et al. Depression in patients with diabetes: does it impact clinical goals? J Am Board Fam Med. 2008;21:392-397.
21. Gonzalez JS, Safren StA, Cagliero E, et al. Depression, self-care and medication adherence in type 2 diabetes. Diabetes Care. 2007;30:2222-2227.
22. Lustmann PJ, Griffith LS, Freedland KE, et al. Cognitive behavioural therapy for depression in type 2 diabetes mellitus. Ann Intern Med. 1998;129:613-621.
23. Peyrot M, Rubin RR. Behavioral and psychosocial interventions in diabetes: A conceptual review. Diabetes Care. 2007;30:2433-2440. (Pubitemid 47547768)
24. Lustmann PJ , Griffiti LS, Freedland KE, et al. Fluoxetine for depression in diabetes. Diabetes Care. 2000;23:618-623.
25. Amsterdam JD, Shults J, Rutherford N, et al. Safety and efficacy of s-citalopram in patients with comorbid major depression and diabetes mellitus. Neuropsychobiology. 2007;54:208-214. (Pubitemid 46558891)
26. Lustmann PJ, Williams MW, Sayur GS, et al. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care. 2007;30:459-466.
27. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants CNS Spectr. 2008;13:7(Suppl 11):27-33.
28. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int clin Psychophamacol. 1996;11, Suppl 4:41-46. (Pubitemid 26371017)
29. Clerc G; Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol. 2001;16:145-151.
30. Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord. 2004;83:233-236. (Pubitemid 39536200)
31. Okumura K, Furukawa TA. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression Clin Drug Invest. 2006;26:135-142.
32. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes. Impact of depressive symptoms on adherence, functions and costs. Arch Intern Med. 2000;160:3278-3285.
33. Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract. 2003;4:7. (Pubitemid 38799825)
34. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment non-adherence: A meta-analysis. Diabetes Care. 2008;31:2398-2403.